Mulmit

Caribou Biosciences, Inc.Caribou Biosciences, Inc.

CRBU Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-3111,159,000-148,344,000-148,125,000-1.59
2024-12-319,994,000-166,616,000-149,105,000-1.65
2023-12-3134,477,000-116,059,000-102,070,000-1.38
2022-12-3113,851,000-106,399,000-99,421,000-1.64
2021-12-319,598,000-66,979,000-66,923,000-2.11

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-02-25Kelly Timothy PChief Technology Officer6,228
2026-02-24Albertson Tina M.Chief Medical Officer1,066
2026-02-24Khan Ruhi AhmadChief Business Officer6,938
2026-02-24Kelly Timothy PChief Technology Officer3,147
2026-02-24MCCLUNG BARBARA GChief Legal Officer6,938
2026-02-20Albertson Tina M.Chief Medical Officer55,000
2026-02-20Albertson Tina M.Chief Medical Officer247,500
2026-02-20Khan Ruhi AhmadChief Business Officer45,000
2026-02-20Khan Ruhi AhmadChief Business Officer202,500
2026-02-20Kelly Timothy PChief Technology Officer45,000
2026-02-20Kelly Timothy PChief Technology Officer202,500
2026-02-20MCCLUNG BARBARA GChief Legal Officer45,000

8-K events

FiledItems
2026-08-13Results of operations · Financial statements and exhibits
2026-06-18Submission of matters to a vote · Financial statements and exhibits
2026-06-11Regulation FD disclosure · Other events · Financial statements and exhibits
2026-05-07Results of operations · Financial statements and exhibits
2026-03-31Regulation FD disclosure · Other events · Financial statements and exhibits
2026-03-05Results of operations · Financial statements and exhibits
2025-11-12Results of operations · Financial statements and exhibits
2025-11-03Results of operations · Regulation FD disclosure · Other events · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Biological Products, (No Diagnostic Substances) — 같은 업종, 그리고 규모가 비슷한 기업Biological Products, (No Diagnostic Substances) — and other companies of a similar size

SEC가 같은 업종(Biological Products, (No Diagnostic Substances))으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Biological Products, (No Diagnostic Substances)) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.